XNAS · Healthcare · Medical - Diagnostics & Research
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
Strong **$2.1B revenue** (+199% YoY) driven by acquisitions masks concerning **$0.53 EPS miss** as integration costs weigh on profitability in diagnostics sector.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | Q4 2025 | 3.05 | 2.52 | -17.38% | $2.11B | ❌ Miss | -3.42% | +21.49% | — |
| 2025-10-22 | Q3 2025 | 3.23 | 3.31 | +2.48% | $2.04B | ✅ Beat | — | — | — |
| 2025-04-30 |
| Q1 2025 |
| 3.08 |
| 3.19 |
| +3.57% |
| $2.00B |
| ✅ Beat |
| -4.11% |
| -8.31% |
| -13.97% |
| 2024-10-23 | Q3 2024 | 3.84 | 3.35 | -12.76% | $2.03B | ❌ Miss | -21.03% | -18.83% | -23.69% |
| 2024-07-24 | Q2 2024 | 3.68 | 3.75 | +1.90% | $2.12B | ✅ Beat | -5.63% | -1.00% | -2.29% |
| 2024-04-24 | Q1 2024 | 3.41 | 3.47 | +1.76% | $2.09B | ✅ Beat | -3.02% | -2.53% | +3.65% |
| 2024-02-21 | Q4 2023 | 3.45 | 3.46 | +0.29% | $2.07B | ✅ Beat | — | — | — |
| 2023-10-25 | Q3 2023 | 3.28 | 3.30 | +0.61% | $2.06B | ✅ Beat | +6.78% | +10.97% | +20.69% |
Showing last 8 quarters.